Galderma presents Dubai data as Galderma stock trades at EUR 189.80

Published on 10/21/2026 at 09:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma stock trades at EUR 189.80 on October 21, 2026. First-half sales rose 24.60 percent to USD 3.10 billion, with 2026 growth guidance at 19%-21%.

Pediatric data and growth outlook

Galderma presented new aesthetics data for an event running from October 21 to October 23, 2026.
First-half 2026 sales rose 24.60 percent to USD 3.10 billion, while full-year growth guidance reached 19%-21%.
Galderma stock trades at EUR 189.80 at 9:48 a.m. CEST at Lang & Schwarz on October 21, 2026.
Citi initiated coverage with a CHF 185.00 price target on October 16, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock (ISIN CH1335392721) was trading at EUR 189.80 at Lang & Schwarz on October 21, 2026, at 9:48 a.m. CEST. Galderma said on October 21, 2026, that it would showcase data from its Injectable Aesthetics portfolio at the AMWC Dubai congress through October 23. The companys growth case rests on a strong first half, when net sales rose 24.60 percent to USD 3.10 billion.

Clinical evidence broadens the story

The latest clinical announcement came on October 15, 2026. According to Galderma, phase II data for nemolizumab in children aged 2 to 11 showed itch-response rates of 56%-72% at Week 16, with benefits sustained through Week 52. Sleep-disturbance scores improved by 70%-78% across cohorts at Week 16, and the treatment produced no new safety signals.

What supports the growth outlook?

The financial foundation is the upgraded 2026 outlook. In its first-half results call, Yahoo Finance reported that Galderma raised constant-currency net sales growth guidance to 19%-21% and confirmed a core EBITDA margin of approximately 26% for 2026. Core EBITDA margin was 25.60% in the first half, up 328 basis points from the first half of 2025. Citi initiated coverage on October 16, 2026, with a Buy rating and a CHF 185.00 price target, according to Markets Insider.

Three dates frame the stock

The recent sequence began on April 22, 2026, when Galderma said shareholders approved a gross dividend of CHF 0.35 per share. On October 15, 2026, the company released pediatric nemolizumab data with 56%-72% Week 16 itch-response rates. On October 21, 2026, Galderma announced its AMWC Dubai presentation, with the event scheduled for October 21-23, 2026.

Dates for the next checkpoints

Galderma scheduled its AMWC Dubai showcase for October 21-23, 2026. The next reporting date listed by TradingView is March 11, 2027, for the second half of 2026.

Stock price and investor perspective

For investors, the key balance is clear: clinical expansion supports the long-term product pipeline, while the 19%-21% sales-growth outlook sets a demanding operating benchmark. Galderma was trading at EUR 189.80 at Lang & Schwarz on October 21, 2026, at 9:48 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.